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Abstract: We describe herein a Toll-like receptor 3 (TLR3) 
targeting delivery system based in mesoporous silica 
nanoparticles capped with the synthetic double stranded RNA 
polyinosinic-polycytidylic acid (poly(I:C)) for controlled cargo 
delivery in SK-BR-3 breast carcinoma cells. Our results showed 
that poly(I:C)-conjugated nanoparticles efficiently targeted breast 
cancer cells due to dsRNA/TLR3 interaction. Such interaction  
also triggered apoptotic pathways in SK-BR-3, significantly 
decreasing cells viability. Poly(I:C) cytotoxic effect in breast 
carcinoma cells was enhanced by loading nanoparticles 
mesopores with the anthracyclinic antibiotic doxorubicin, a 
commonly used chemotherapeutic agent. 
 
Breast cancer is the most commonly  diagnosed 
malignancy and the deadliest among women worldwide, 
accounting for 25% of all cancer cases and 15% of all cancer 
deaths.[1] Breast cancer incidence is especially high in developed 
countries, where it seems to be destined to augment due to the 
expected increase of elderly population; more than 40% of 
breast cancer patients, in fact, are women aged over 65.[2] 
Therefore, improving existing breast cancer treatment strategies, 
that still present significant adverse effects or limited efficacy in 
some molecular subtypes of the disease and in metastatic 
patients,  is a medicine challenge. 
An interesting field in cancer-fighting research is 
immunotherapy, not directed to eliminate cancer cells but to 
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against tumours.[3] In recent years different kinds of 
immunotherapeutic approaches have been developed following 
two main paths: immune checkpoints blockade, to avoid 
immunosuppressive mechanisms often enhanced in tumours, 
and the use of ligands for Toll-like receptors (TLRs) to potentiate 
immune stimulatory pathways.In the present work, we focused 
on this second option, taking into account that the innate 
immunity receptors TLRs are functionally expressed in  different 
types of tumour cells, where they may influence cancer growth 
and host immune responses.[4] 
Currently, only few TLRs ligands have US Food and Drug 
Administration approval: Imiquimod, a TLR7 agonist used for the 
treatment of non-invasive transitional cell carcinoma of bladder, 
and two TLR2/TLR4 agonists, the bacillus Calmette-Guérin 
(BCG), applied to superficial basal cell carcinoma, and the 
monophosphoryl lipid A (MPL), approved as a component in 
human papillomavirus (HPV)-16/18 vaccine.[5] However, another 
interesting compound that has shown cytotoxic effects in 
different types of cancer is polyinosinic-polycytidylic acid 
(poly(I:C)), a synthetic dsRNA agonist of TLR3.dsRNA efficacy  
in oncologic treatments was tested in different studies carried  
out between 70s and 90s. In the last decade, Salaun and 
coworkers not only found that poly(I:C) can directly kill cancer 
cells of different breast cancer cell lines inducing apoptosis 
through a complex pathway that determines the production of 
type I interferons and the consequent activation of the apoptotic 
effector caspase 3, the death ligand TRAIL and the tumour 
suppressor  protein  p53,  but  also  demonstrated  that    breast 
carcinoma patients overexpressing TLR3 respond adequately to 
dsRNA adjuvant treatments.[6] 
From another point of view the design of gated silica 
mesoporous materials for mass transport and controlled 
release has recently attracted a great attention.  Since  the 
first example reported by Fujiwara and coworkers in 2003, [7] 
several mesoporous gated materials displaying controlled 
release triggered by target chemical,[8] physical[9]and 
biochemical[10] stimuli have been  described.  Furthermore,  
the possibility of retaining the cargo and release it on 
command and spatiotemporally is a relevant feature that 
makes this technology suitable for the development of new 
efficient and safe drug delivery nanodevices. In this context, 
mesoporous silica nanoparticles (MSNs) supports are 
widely used in nanomedicine applications thanks to their 
unique characteristics, such as high homogeneous porosity, 
inertness, robustness, thermal stability and high loading 
capacity.[11] Owing to their properties, these supports have 
been reported to be able to act as multifunctional delivery 
platforms for the controlled release of therapeutic agents   for 
 
 
the treatment of a wide variety of disease models, including 
cancer models, at cellular and in vivo levels.[12] MSNs  are 
able to enclose and protect hydrophobic and hydrophilic 
drugs during their transport, overcoming common issues 
such as poor solubility and stability or the existence of 
undesired side effects.[13] In addition, surface  
functionalization with specific targeting moieties allows  
these nanodevices to gain selectivity towards specific cells 
types.[14]In order to achieve this, specific biomolecules 
whose receptors are overexpressed in target cells can be 
anchored to the surface of the nanoparticles. Until now, 
several specific ligands of overexpressed cancer cell 
receptors have been studied[15] to take a step forward to an 
active and specific tumor-targeting  strategy.  However, this  
is still an incipient area of research using MSNs and there is 




poly(I:C) that would block the pores thus inhibiting cargo 
release.Since TLR3 is located in plasma membrane and in 
the endosomal compartment, we speculate that poly(I:C) 
would interact with TLR3, resulting in caspase-3 activation 
and receptor-mediated endocytosis of nanoparticles in  
breast cancer cells. Once endocytosed, lysosomal enzymes 
would degrade poly(I:C) chains, induce  the  uncapping  of  
the pores and release the entrapped guest. In the case of    
S2  nanoparticle,  loaded  with  doxorubicin,  it  was expected 
asynergistic effect due to the effect of poly(I:C) and the 
cytotoxicity of doxorubicin via topoisomerase-2 inhibition.[17] 
In order to prepare the gated nanodevices, silica 
mesoporous (MCM-41-type)  nanoparticles were  selected as 
inorganic scaffolds. Calcined MCM-41 nanoparticles were 
loaded with a suitable dye (sulforhodamine B) and the 
external surface was functionalized with 3- 
aminopropyltriethoxisilane. Then, the reaction of the 
anchored   amino   groups   with   the   previously     activated 
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Scheme 1. Expected performance of S2 material in SK-BR-3 breast 
cancer cells. 1) Poly(I:C) decorated MSNP recognition by TLR3 and 
receptor-mediated endocytosis; TLR3 activation triggers apoptotic 
cascade; 2) MSNs entrapment in endosome;  3)  Intracellular  transport 
and endosome fusion with lysosome; 4) MSNs degradation by lysosomal 
digestive enzymes and doxorubicin  release.  Doxorubicin  intercalation 













































topoisomerase II complex, leading to cell  death. 
 
In this context, and bearing in mind the interest in the 
design of new delivery systems, we were interested in 
attempting the design of targeted delivery nanoparticles to 
breast cancer cell. In this scenario, despite the use  of  
ligands for TLR3 (such as poly(I:C)) in certain clinical 
studies, their combination with nanoparticles has not been 
reported yet. Here, we describe a targeting delivery system 
based in MSNs decorated with synthetic dsRNA (poly(I:C)), 
as a novel  vehicle for drug delivery in breast cancer cells. 
We took advantage of a breast cancer cell system (SK-BR- 
3)  which  expresses  TLR3[16]   to  characterize  the  effect   of 
dsRNA-conjugated nanoparticles in tumor cell viability. Our 
delivery system is depicted in Scheme 1. It is based on the 
use of MSNs as carrier support, loaded with a suitable 
reporter (i.e. sulforhodamine B, S1material) or with a 
cytotoxic drug (i.e. doxorubicin, S2 material) and externally 
functionalized   with   the   synthetic   double-stranded    RNA 
2θ/deg 
Figure 1. Powder X-ray diffraction pattern of (a) as made MCM-41, (b) 
calcined MCM-41 and (c) solid S1 showing the typical reflections of MCM-
41 hexagonal array. TEM representative images of (D) calcined MCM-41 
and (E) solid S1 showing typical porosity of MCM-41 mesoporous matrix. 
 
The structure of the starting MSNs and of the final S1 
material was confirmed by X-ray diffraction and TEM 
studies (Figure 1). The X-ray diffraction pattern  of S1 
showed the characteristic diffraction peak (100)  indicating 
that the structure of the mesoporous scaffold was not 
modified by dye loading process and further  
functionalization to obtain the capped material. N2 
adsorption–desorption isotherm of S1 (see Supporting 
Information)  was  typical  of  capped  mesoporous   systems, 
and a significant decrease in the N2 volume adsorbed and 
surface area (116.5 m2 g-1) was observed when compared 











Moreover, contents of 15.6 mg.g
-1
SiO2 of  dye  and  191.8  
mg. g
-1
SiO2 of poly(I:C) on solid S1 were determined by 
elemental analysis and  thermogravimetric studies. 
To test the gating properties of the solid, in vitro studies   





In a typical experiment, 1 mg of S1  was suspended in 
500 µL of deionized water. The suspension was divided into 
two aliquots of 250 µL and 1 mL of 10 mM PBS or 1 mL of 
purified lysosomal extract was added. The purified 
lysosomal extract was obtained using the Lysosome 
Isolation Kit (LYSISO1). The suspensions were stirred and 
aliquots were taken at scheduled times. The amount of dye 
released     from     S1     was     determined     by  monitoring 
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time (λex=554 nm, λem =575 nm).In PBS medium, a poor 
delivery was found(see Figure 2) indicating that most of the 
dye remained in the nanoparticles. In contrast, in the 
lysosomal extract media a large release of sulforhodamine    
B was observed. This was attributed to the enzymatic 
degradation of poly(I:C) chains which resulted in cargo 
delivery. The obtained results confirmed the triggering 
event hypothesis, i.e. whereas solid  S1  displayed  a  very 
low release, the presence of  lysosomal  enzymes  induced 
the delivery of the entrapped  guest. 
Controlling cell targeting and penetrability of drugs is an 
important issue in modern medicine. Therefore, after 
demonstrating    the    effective    capping    and    delivery   in 
lysosomal  extract  of  S1,  we  evaluated  S1-induced   TLR3 
Figure 2. Sulforhodamine B release profile from solid S1 (a) in 10 mM PBS 
medium and (b) in presence of purified lysosomal extract. 
internalization in breast cancer SK-BR-3 cells, which 




























Figure 3. Internalization and release of  sulforhodamine B or doxorubicin by  S1  and S2  nanoparticles,  respectively,  in SK-BR-3 cells. Cells were 
treated with 50 μg/ml of equivalent poly(I:C) in S1 or S2 nanoparticles for 48h. DAPI nuclei staining was carried out before of confocal microscope 
observation. Representative phase contrast (PhC), DAPI, sulforhodamine B  (ShR),  doxorubicin  (Dox)  and  combined  (Merge)  images  are  shown. 
White symbols indicate cells apoptotic degradation (nuclei fragmentation, cytoplasm degeneration). In  S2-treated  cells  DAPI  and  doxorubicin  co- 
localize in the nuclei. 
 
 
As stated above, interaction of the TLR3 receptor with 
poly(I:C), has been described to induce its rapid 
internalization and trigger caspase-3 activation and cell 
death. In order to demonstrate the interaction of  
nanoparticles S1 with TLR3, followed by  internalization, 
cargo delivery and cell death, we evaluated the effect of the 
nanoparticles on SK-BR-3 cells. In a typical experiment SK- 
BR-3 cells were incubated for 48h withS1, and 
sulforhodamine B release was monitored by confocal 
microscopy.Remarkably, S1-treated SK-BR-3 cells clearly 
exhibited sulforhodamine Brelease from nanoparticles (see 
Figure 3). 
In another step, we evaluated cell viability of S1 inSK- 
BR-3 cells. Figure 5 shows  dose-response  experiments 
after 48h when using S1 as a function of the amount of 
poly(I:C) in the nanoparticles. As seen,treatment with S1 
nanoparticles produced a decrease in SK-BR-3 cells 
viability with IC50  values of ca. 10
2
μg/mL. As stated above    it 
has been reported that poly(I:C) can directly kill cancer cells 
inducing apoptosis and therefore cell viability of free  
poly(I:C)  on   SK-BR-3  cells  was  also  evaluated  using    a 
similar experimental procedure to that followed for S1. 
However, is this case amounts of poly(I:C) of ca. 103μg/mL 
were only able to reduce cell viability to ca. 80%. These 
experiments  allowed  us to  conclude  that  poly(I:C)  is much 
more effective killing SK-BR-3 cells when  incorporated  in 
S1, compared with free poly(I:C), most likely due to an 
“enhanced concentration effect” due to the presence of a 
large amount of poly(I:C) on the surface of  S1. 
Moreover, in order to corroborate the specific targeting   
of S1 in SK-BR-3 cells, we also performed competition 
assays   with    the    TLR3/dsRNA   complex   inhibitor   from 
Calbiochem. In these experiments, the  viability of    SK-BR-3 
cascade. In addition, we envisioned that the toxicity of the 
nanoparticles could be enhanced via the preparation of  a 
new carrier also capped with poly(I:C) but  loaded  in  this 
case with the cytotoxic  doxorubicin  (nanoparticles S2). 
Solid S2 was prepared using a similar procedure to that 
followed for S1 and was fully characterized (see Supporting 
Information for details). 
The X-ray diffraction pattern of S2 shows the typical 
characteristic diffraction peak (100). Moreover, N2 
adsorption–desorption isotherm of S2 was typical of capped 
mesoporous materials, with a surface area of 180,46 m2g- 
1
.Finally contents of 204,5 mg.g
-1
SiO2 of doxorubicin  and  
79,9 mg.g
-1
SiO2  of poly(I:C) on solid S2 were   determined. 
The possibility to retain cargo inside a carrier until  its 
target is reached is an important and  highly desirable 
feature in drug delivery systems to reduce side effects. In 
this context, in vitro release studies of doxorubicin from 
S2were performed in water (10 mM PBS) and in the 
presence of lysosomal extract (see Figure 4) following a 
similar procedure to that used for S1 (vide ante). In PBS a 
remarkable baseline was observed, which indicated that 
doxorubicin remained in the nanoparticles without release. 
For instance, cargo delivery was lower than 10% at 24h. In 
contrast, cargo release in the presence of lysosomal extract 
was clearly found as an increase of the doxorubicin 









cells significantly decreased (to ca. 50%) after  treatment  
with S1, while previous cell exposure to the inhibitor and 
further treatment with S1 resulted in a cell viability of ca. 
100% (see Figure 4b). This evidence clearly suggested the 
direct interaction between the gating and targeting synthetic 
dsRNApoly(I:C) in S1 and the TLR3 receptor. Moreover, it 
was  also  observed that  cell  exposure to the inhibitor  or   to 
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bare nanoparticles (data not shown) had no effect on cell 
viability (see Figure 4b). Additionally, to  further  prove  that 
the viability decrease when SK-BR-3  cells are  exposed  to 
S1 was due to the interaction of poly(I:C) with the TLR3 
receptor and the activation of the apoptotic pathway (see 
Scheme 1), we confirmed the activation of caspase-3 by 
western blot assays after treatment of SK-BR-3  cells with 
S1. All these data indicated that S1 triggers cell death in 
breast cancer SK-BR-3 cells by induction  of  apoptosis,  
which is accomplished through TLR3-induced  
internalization. 
One advantage when using gated MSNs is the 
possibility of design poly-functional carriers with enhanced 
functionalities. As we have seen above, the design of S1 
make full use of the great affinity of the synthetic 
dsRNApoly(I:C) to TLR3 receptor overexpressed inbreast 
cancer  SK-BR-3  cells  and  the  activation  of  the   apoptotic 
Figure 4. Doxorubicin release profile from solid S2 (a) in 10 mM PBS 
medium and (b) in presence of purified lysosomal   extract. 
 
Cell viability studies of S2 inSK-BR-3 cells performing 
dose response experiments were carried out and the 
results are shown in Figure 5a. Treatment of SK-BR-3 cells 
with S2 resulted in a remarkable decrease in cell viability 
when compared with free poly(I:C) and with S1. For 
instance, for S2 IC50 values of ca. 10
1
μg/mL were found, 
which  indicated  that  S2  showed  a  similar  toxicity  than S1 
when S2 was used in concentrations 10 times lower. Cell 
death was also evaluated by confocal microscopy (see 
Figure 3). Cells showing apoptotic degradation (nuclei 
fragmentation, cytoplasm degeneration) and a 
colocalization in the nuclei of doxorubicin  and  DAPI  dye  
was observed. The performed cellular studies  suggested  
that  S2  induced  cell  death  in  SK-BR-3  cellsvia  both     (i) 
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interaction between capping molecules of poly(I:C) and the 
TLR3 receptor which induced caspase-3 activation and (ii) 
doxorubicin delivery. As stated above, the specific targeting  
of TLR3 by poly(I:C) has previously been  described  in 
breast cancer cells, however this is the first time that 
poly(I:C) has been combined with MSNs, additionally 
containing doxorubicin. Remarkably the nanoparticles 
capped with poly(I:C) andloaded with  doxorubicin (i.e.  S2) 
are much more toxic than those only functionalized with 
poly(I:C) (i.e. S1) suggesting a synergistic effect in killing 
cancer cells. Moreover targeting of doxorubicin to TLR3- 
expressing cells would not only enhance its antitumor effect 
yet would also diminish toxicity in normal  cells. 
 
a) 
1 0 0 
S 1 
Hiltonol (Oncovir Inc.), Ampligen (Hemixpherx) or IPH3102 
(Innate Pharma), and their antineoplasic effect is being 
evaluated in different clinical trials.[18] Moreover,  as  the 
TLR3 receptor has also been overexpressed in other 
cancer cells (e.g. melanoma,[6] prostate[19]), the specific 
targeting of chemoterapeutic agents to TLR3 receptor in 
nanosystems such as S2 could be an effective strategy to 
treat  different  malignancies  in  which  TLR3 overexpression 
has been described. 
In conclusion, we have shown that synthetic dsRNA- 
conjugated nanoparticles effectively target TLR3- 
expressing breast cancer cells, and produce a TLR3- 
mediated internalization of the nanoparticles, which  
correlates with a caspase-dependent apoptosis induction. 
Importantly, the nanoformulation improved cytotoxic effects 
when compared to naked poly(I:C) on breast cancer cells. 



























































































1 0 3 
S 2 
  r  oly(I:C)  can act as nano-carriers for the chemotherapeutic drug 
doxorubicin, improving the cytotoxicity of dsRNA-  
conjugated nanoparticles. It is worth noting that TLR3 levels 
can be modulated by retinoic acid (RA) and other antitumor 
drugs.[16] Hence, by upregulating TLR3 levels with such 
treatments,  it  would  be  possible  to  further  enhance     the 
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tumors thus opening up new  opportunities to  be  exploited. 
In particular, targeting innate immunity sensors with dsRNA-
conjugated nanodevices may provide an effective strategy for 
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Targeting Innate Immunity with 
dsRNA-Conjugated Mesoporous 
Silica Nanoparticles Promotes Anti- 
Tumor Effects on Breast Cancer Cells 
 
 
A new drug delivery system based in mesoporous silica nanoparticles capped with the synthetic double stranded RNA polyinosinic- 
polycytidylic acid (poly(I:C)) for targeting breast carcinoma cells is reported. 
